KR20220080102A - B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법 - Google Patents

B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법 Download PDF

Info

Publication number
KR20220080102A
KR20220080102A KR1020227011839A KR20227011839A KR20220080102A KR 20220080102 A KR20220080102 A KR 20220080102A KR 1020227011839 A KR1020227011839 A KR 1020227011839A KR 20227011839 A KR20227011839 A KR 20227011839A KR 20220080102 A KR20220080102 A KR 20220080102A
Authority
KR
South Korea
Prior art keywords
ser
gly
prt
homo sapiens
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227011839A
Other languages
English (en)
Korean (ko)
Inventor
차오 왕
미첼 누센즈웨이그
Original Assignee
더 락커펠러 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 락커펠러 유니버시티 filed Critical 더 락커펠러 유니버시티
Publication of KR20220080102A publication Critical patent/KR20220080102A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227011839A 2019-09-11 2020-09-11 B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법 Pending KR20220080102A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962898735P 2019-09-11 2019-09-11
US62/898,735 2019-09-11
US202062982276P 2020-02-27 2020-02-27
US62/982,276 2020-02-27
PCT/US2020/050509 WO2021050954A1 (en) 2019-09-11 2020-09-11 Compositions and methods related to human neutralizing antibodies to hepatitis b

Publications (1)

Publication Number Publication Date
KR20220080102A true KR20220080102A (ko) 2022-06-14

Family

ID=74866658

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011839A Pending KR20220080102A (ko) 2019-09-11 2020-09-11 B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법

Country Status (7)

Country Link
US (1) US20220315645A1 (enExample)
EP (1) EP4021503A4 (enExample)
JP (1) JP7629649B2 (enExample)
KR (1) KR20220080102A (enExample)
CN (1) CN114728066A (enExample)
CA (1) CA3154556A1 (enExample)
WO (1) WO2021050954A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023287352A2 (en) * 2021-07-15 2023-01-19 National University Of Singapore Anti-hbv antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500515A (ja) * 1986-06-20 1989-02-23 スクリップス　クリニック　アンド　リサーチ　ファウンデーション Ｂ型肝炎ウィルス表面抗原のプレｓ領域のｔ及びｂ細胞エピトープ
US7390619B1 (en) * 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2594922A1 (en) * 2005-01-14 2006-07-20 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize hepatitis b virus
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
AU2013287516B2 (en) * 2012-07-10 2016-07-07 Green Cross Corporation An antibody composition for prevention or treatment of mutant hepatitis B virus infection
KR20150070181A (ko) * 2012-09-27 2015-06-24 크루셀 홀란드 비.브이. B형 간염 바이러스에 결합하고 이를 중화시킬 수 있는 인간 결합 분자 및 그의 용도
SG10201804975PA (en) * 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression

Also Published As

Publication number Publication date
EP4021503A4 (en) 2024-02-14
CA3154556A1 (en) 2021-03-18
JP2022547551A (ja) 2022-11-14
WO2021050954A1 (en) 2021-03-18
EP4021503A1 (en) 2022-07-06
CN114728066A (zh) 2022-07-08
JP7629649B2 (ja) 2025-02-14
US20220315645A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
Wang et al. A combination of human broadly neutralizing antibodies against hepatitis B virus HBsAg with distinct epitopes suppresses escape mutations
JP7171809B2 (ja) Ｂ型肝炎ウイルスを強力に中和する抗体及びその使用
Hehle et al. Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers
AU2015206002B2 (en) Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen
WO2013185558A1 (zh) 用于治疗hbv感染及相关疾病的多肽及抗体
CN114630680B (zh) 用于治疗乙型肝炎病毒感染的抗体组合物和方法
TWI904172B (zh) 抗hbv抗體及使用方法
KR20220080102A (ko) B형 간염에 대한 인간 중화 항체와 관련된 조성물 및 방법
Kim et al. Construction of a humanized antibody to hepatitis B surface antigen by specificity-determining residues (SDR)-grafting and de-immunization
US20240327500A1 (en) Anti-hbv antibodies and uses thereof
RU2803082C2 (ru) Антитела против вируса гепатита в и их применение
HK40074417A (en) Antibodies that neutralize hepatitis b virus and uses thereof
HK40074418A (en) Antibodies that neutralize hepatitis b virus and uses thereof
CN117042797A (zh) 用于治疗乙型肝炎病毒感染的组合物和方法
HK40073510B (zh) 用於治疗乙型肝炎病毒感染的抗体组合物和方法
HK40073510A (en) Antibody compositions and methods for treating hepatitis b virus infection
Shamseldin Development of Research Tools for Studying Hepatitis B Virus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000